Humanwell’s North America expansion started in 2008, with the establishment of PuraCap Pharmaceutical in New Jersey. PuraCap specializes in research and development, manufacturing, and commercialization of soft gel prescription generic and OTC products. With its headquarters, R&D team, sales and marketing team in New Jersey, its state-of-the-art cGMP manufacturing facility (annual soft gel capacity of up to 6 billion) in Wuhan, and total employees of 300+, PuraCap supplies major US wholesalers and pharmacy chains with more than 200 products carrying major and store brands.

Humanwell acquired Epic Pharma, LLC in 2016. Epic is a leader in R&D, manufacturing and commercialization of oral solid dose and controlled substance prescription generics drugs in the US. Located in New York with employees of 230, Epic manufactures high quality prescription generics on behalf of its pharmaceutical clients such as Sandoz, and supplies to major wholesalers and group purchase organizations (GPOs) prescription generics under its own label. In addition to a total of 40 marketed products, the company owns a pipeline of 20 ANDAs, 12 filed to the FDA with pending approvals, and 10 in late stage development.